Institutional shares held 161 Million
225K calls
80.8K puts
Total value of holdings $8.82B
$12.3M calls
$4.41M puts
Market Cap $2.14B
39,222,600 Shares Out.
Institutional ownership 411.71%
# of Institutions 614


Latest Institutional Activity in TECH

Top Purchases

Q2 2025
Citadel Advisors LLC Shares Held: 2.47M ($135M)
Q2 2025
Norges Bank Shares Held: 1.91M ($104M)
Q2 2025
Millennium Management LLC Shares Held: 1.64M ($89.6M)
Q2 2025
T. Rowe Price Investment Management, Inc. Shares Held: 1.24M ($67.6M)
Q2 2025
Rgm Capital, LLC Shares Held: 2.2M ($120M)

Top Sells

Q2 2025
Price T Rowe Associates Inc Shares Held: 8.85M ($483M)
Q2 2025
Select Equity Group, L.P. Shares Held: 2.92M ($159M)
Q2 2025
Massachusetts Financial Services CO Shares Held: 1.66M ($90.5M)
Q2 2025
Ubs Group Ag Shares Held: 992K ($54.2M)
Q2 2025
State Street Corp Shares Held: 5.86M ($320M)

About TECH

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.


Insider Transactions at TECH

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
394K Shares
From 18 Insiders
Grant, award, or other acquisition 12.7K shares
Exercise of conversion of derivative security 381K shares
Sell / Disposition
301K Shares
From 11 Insiders
Payment of exercise price or tax liability 250K shares
Open market or private sale 50.6K shares

Track Institutional and Insider Activities on TECH

Follow BIO-TECHNE Corp and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TECH shares.

Notify only if

Insider Trading

Get notified when an Bio Techne Corp insider buys or sells TECH shares.

Notify only if

News

Receive news related to BIO-TECHNE Corp

Track Activities on TECH